[Form 4] COPT DEFENSE PROPERTIES Insider Trading Activity

COPT Defense Properties reported 24 consecutive quarters of year-over-year FFO growth and 84% tenant retention for the first half of 2026. It raised vacancy leasing targets by 20%, maintained a 95.2% lease rate in Northern Virginia, and expects same-property cash NOI growth to moderate in H2. Guidance includes ~8.5% development cash yields and 100% retention on eight large government leases.

COPT DEFENSE PROPERTIES (CDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cdp06302026ex991.htm EX-99.1 Document Exhibit 99.1 COPT Defense Properties Supplemental Information + Earnings Release - Unaudited For the Period Ended 6/30/26 OVERVIEW Summary Description 1 Equity Research Coverage 2 Selected Financial Summary Data 3 Selected Portfolio

Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral, raising its price target to $4.00. The company reported positive Phase 1 and Phase 2 results for RP-A501 in Danon disease, with FDA alignment on pivotal trial design. Rocket secured a $150M credit facility to fund operations until Q3 2028. Analysts have mixed views on the stock's potential.

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.

Pinterest (PINS) appointed Amazon's James Dibbo as its new CFO. The company's stock has shown mixed performance, with a recent 7-day return of 7.52% but a 1-year return of -36.11%. Analysts have varying views on its valuation, with some seeing it as undervalued at $20.31 per share compared to a fair value estimate of $29.05, while others note its high P/E ratio of 46.2x.